EA201291211A1 - Фармацевтические композиции, содержащие гидроморфон и налоксон - Google Patents

Фармацевтические композиции, содержащие гидроморфон и налоксон

Info

Publication number
EA201291211A1
EA201291211A1 EA201291211A EA201291211A EA201291211A1 EA 201291211 A1 EA201291211 A1 EA 201291211A1 EA 201291211 A EA201291211 A EA 201291211A EA 201291211 A EA201291211 A EA 201291211A EA 201291211 A1 EA201291211 A1 EA 201291211A1
Authority
EA
Eurasian Patent Office
Prior art keywords
naloxone
pharmaceutical compositions
compositions containing
containing hydromorphone
hydromorphone
Prior art date
Application number
EA201291211A
Other languages
English (en)
Inventor
Хелен Кэтлин Дэнэгер
Хассан Мохаммад
Малькольм Вэлден
Джеффри Джерард Хейз
Джонатон Оливер Уайтхаус
Тиннаям Наганатан Кришнамурти
Рикардо Альберто Варгас Ринкон
Original Assignee
Эро-Селтик С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42983574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201291211(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эро-Селтик С.А. filed Critical Эро-Селтик С.А.
Publication of EA201291211A1 publication Critical patent/EA201291211A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к фармацевтическим лекарственным формам пролонгированного высвобождения, их производству, а также их применению для введения людям.
EA201291211A 2010-05-10 2011-05-10 Фармацевтические композиции, содержащие гидроморфон и налоксон EA201291211A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10162428 2010-05-10
PCT/EP2011/057566 WO2011141488A2 (en) 2010-05-10 2011-05-10 Pharmaceutical compositions comprising hydromorphone and naloxone

Publications (1)

Publication Number Publication Date
EA201291211A1 true EA201291211A1 (ru) 2013-05-30

Family

ID=42983574

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201291211A EA201291211A1 (ru) 2010-05-10 2011-05-10 Фармацевтические композиции, содержащие гидроморфон и налоксон

Country Status (35)

Country Link
US (1) US9700508B2 (ru)
EP (1) EP2568967B2 (ru)
JP (1) JP5671609B2 (ru)
KR (2) KR101858797B1 (ru)
CN (2) CN105832687A (ru)
AP (1) AP3441A (ru)
AR (1) AR083150A1 (ru)
AU (1) AU2011252039B2 (ru)
BR (1) BR112012028773A2 (ru)
CA (1) CA2739751C (ru)
CH (1) CH705273B1 (ru)
CL (1) CL2012003012A1 (ru)
CO (1) CO6640216A2 (ru)
CR (1) CR20120549A (ru)
DE (1) DE112011101605T5 (ru)
DK (1) DK178741B1 (ru)
EA (1) EA201291211A1 (ru)
EC (1) ECSP12012236A (ru)
ES (1) ES2408343B2 (ru)
GB (1) GB2492037A (ru)
GT (1) GT201200304A (ru)
IL (1) IL222772B (ru)
MX (1) MX347105B (ru)
MY (1) MY157673A (ru)
NI (1) NI201200157A (ru)
NO (1) NO20121414A1 (ru)
NZ (2) NZ603497A (ru)
PE (1) PE20130657A1 (ru)
SE (1) SE1251371A1 (ru)
SG (1) SG184523A1 (ru)
TN (1) TN2012000488A1 (ru)
TW (2) TWI483748B (ru)
UA (1) UA106278C2 (ru)
WO (1) WO2011141488A2 (ru)
ZA (1) ZA201207603B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103002881B (zh) 2010-05-10 2015-09-02 欧洲凯尔特公司 载有活性剂的颗粒与额外活性剂的组合
WO2011141488A2 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
CN103002882B (zh) 2010-05-10 2016-03-02 欧洲凯尔特公司 不含活性剂之颗粒及包含其之片剂的制备
TWI566786B (zh) * 2012-09-03 2017-01-21 第一三共股份有限公司 含有氫化嗎啡酮鹽酸鹽之經口用徐放性醫藥組成物
CA2881144A1 (en) * 2012-11-09 2014-05-09 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
US9517208B2 (en) * 2013-03-15 2016-12-13 Purdue Pharma L.P. Abuse-deterrent dosage forms
GB201313915D0 (en) 2013-08-02 2013-09-18 Johnson Matthey Plc Process
UA116405C2 (uk) * 2013-11-13 2018-03-12 Євро-Селтік С.А. Гідроморфон та налоксон для лікування болю та синдрому опіоїдної дисфункції кишечнику
CA2847781C (en) * 2014-03-28 2019-03-12 Purdue Pharma Reducing drug liking in a subject
EP3229785A2 (de) * 2014-12-08 2017-10-18 Develco Pharma Schweiz AG Naloxon-monopräparat und mehrschichttablette
EP4103181A4 (en) * 2020-02-14 2024-03-06 Teikoku Pharma USA, Inc. TOPICAL NALOXONE COMPOSITION AND METHOD OF USE THEREOF

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE49324B1 (en) 1979-12-19 1985-09-18 Euro Celtique Sa Controlled release compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
HU190619B (en) 1983-11-11 1986-09-29 Bezzegh,Denes,Hu Process for producing tablets with controlled dissolution of active ingredients
EP0164669B1 (de) 1984-06-13 1991-01-23 Röhm Gmbh Verfahren zum Überziehen von Arzneiformen
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
EP0352361A1 (en) 1988-07-29 1990-01-31 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
FR2653337B1 (fr) 1989-10-23 1992-02-07 Dow Corning Sa Element a liberation prolongee et procede pour le fabriquer.
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE4443105C2 (de) 1994-12-03 1997-03-13 Hoechst Ag Verfahren zur Herstellung Molsidomin-haltiger Tabletten
US6488961B1 (en) 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
DE69834195T2 (de) 1997-07-02 2007-03-29 Euro-Celtique S.A. Stabilisierte tramadol formulierungen mit verzögerter freisetzung
DK1041987T3 (da) 1997-12-22 2006-08-21 Euro Celtique Sa Oral farmaceutisk doseringsform omfattende en kombination af en opioid-agonist og naltrexon
ECSP003314A (es) 2000-01-11 2000-03-22 Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide y un - agonista
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EE05171B1 (et) 2000-02-08 2009-06-15 Euro-Celtique, S.A. Peroraalne ravimvorm, mis sisaldab opioidagonisti vabanevas vormis ja eraldatud opioidantagonisti, meetod selle valmistamiseks ning selle kasutamine meditsiinis
US20040115133A1 (en) 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
JP4522652B2 (ja) * 2001-05-11 2010-08-11 エンドー ファーマシューティカルズ， インコーポレイティド 乱用防止制御放出オピオイド投薬形態
CA2778114A1 (en) * 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
CN100356907C (zh) 2001-06-08 2007-12-26 恩德制药公司 利用丙烯酸酯聚合物的控释剂型和其制备方法
EP1414418A1 (en) 2001-08-06 2004-05-06 Euro-Celtique S.A. Compositions and methods to prevent abuse of opioids
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
PT1414451E (pt) * 2001-08-06 2009-07-31 Euro Celtique Sa Formulações agonistas de opióides com antagonista libertável e sequestrado
NZ531152A (en) 2001-08-23 2005-11-25 Akzo Nobel Nv Process for the preparation of a 14 hydroxynormorphinone derivative
DE10146275A1 (de) 2001-09-18 2003-04-24 Gruenenthal Gmbh Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
GEP20064022B (en) 2002-04-05 2007-01-10 Euro Celtique Sa Pharmaceutical formulations comprising oxycodone and naloxone
DE10215131A1 (de) * 2002-04-05 2003-10-16 Euro Celtique Sa Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
NZ536975A (en) 2002-07-04 2006-10-27 Janssen Pharmaceutica Nv Solid dispersions of a poorly soluble bioactive compound comprising two different polymer matrixes
PT1615646E (pt) 2003-04-08 2015-02-12 Progenics Pharm Inc Formulações farmacêuticas com metilnaltrexona
MXPA05010819A (es) 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
CN1767855A (zh) 2003-04-08 2006-05-03 普罗热尼奇制药公司 包含缓泻剂和外周阿片拮抗剂的便秘的组合疗法
AR047936A1 (es) 2003-04-30 2006-03-15 Purdue Pharma Ltd Forma de dosificacion transdermica resistente a la manipulacion
US9114199B2 (en) 2003-07-31 2015-08-25 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing acrylic copolymer for controlled delivery of therapeutic agent
US20050079221A1 (en) 2003-10-10 2005-04-14 Groenewoud Pieter Jurjen Ibuprofen narcotic composition and method for making same
US20050232987A1 (en) 2004-03-12 2005-10-20 Viswanathan Srinivasan Dosage form containing a morphine derivative and another drug
US20050165038A1 (en) 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
GEP20084454B (en) 2004-02-06 2008-08-10 Euro Celtique Sa Methods for making 3-o-protected morphinones and 3-o-protected morphinone dienol carboxylates
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
TWI483944B (zh) 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US7700626B2 (en) 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
EP1814528A2 (en) 2004-10-08 2007-08-08 Rubicon Research Private Limited Process for making a highly compressible controlled delivery compositions of metformin
GB0423103D0 (en) 2004-10-19 2004-11-17 Boots Healthcare Int Ltd Therapeutic agents
BRPI0606587A2 (pt) 2005-01-20 2009-07-07 Progenics Pharmaceuticais Inc uso de metilnaltrexona e compostos correlatos para tratar disfunção gastrintestinal pós-operatória
KR20090029856A (ko) 2005-01-28 2009-03-23 유로-셀띠끄 소시에떼 아노님 알코올 저항성 제형
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
NL1028460C2 (nl) * 2005-03-04 2006-09-06 Sara Lee De Nv Inrichting voor het bereiden en afgeven van al dan niet althans gedeeltelijk opgeschuimde dranken.
JP4741865B2 (ja) 2005-03-24 2011-08-10 共和薬品工業株式会社 ペルゴリド錠剤の製造方法
US20070026025A1 (en) 2005-04-12 2007-02-01 Aquegel Cosmetics, Llc Topical ointment and method for making and using same
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070059360A1 (en) 2005-07-29 2007-03-15 Ashish Jaiswal Water-dispersible anti-retroviral pharmaceutical compositions
US20070048364A1 (en) 2005-08-04 2007-03-01 Yingxu Peng Free flowing granules containing carbomer
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
EP1962808B1 (en) 2005-12-14 2010-09-29 F. Hoffmann-La Roche AG Hcv prodrug formulation
US20070141147A1 (en) 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102006051020A1 (de) 2006-10-26 2008-04-30 Evonik Röhm Gmbh Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung
GB2447898B (en) 2007-03-24 2011-08-17 Reckitt Benckiser Healthcare A tablet having improved stability with at least two actives
EP2379066B1 (en) 2008-09-16 2014-03-26 Imuneks Farma Ilaç Sanayi Ve Ticaret A.S. Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases
ES2586439T3 (es) 2008-09-18 2016-10-14 Purdue Pharma Lp Formas farmacéuticas de dosificación que comprenden poli (E-caprolactona)
MX2011003050A (es) 2008-09-24 2011-04-11 Evonik Roehm Gmbh Composicion farmaceutica de liberacion controlada ph dependiente para no opioides con resistencia contra la influencia de etanol.
ES2532877T3 (es) 2008-09-24 2015-04-01 Evonik Röhm Gmbh Composición farmacéutica opioide de liberación controlada dependiente del pH con resistencia frente a la influencia del etanol
CN102281876A (zh) 2008-10-30 2011-12-14 格吕伦塔尔有限公司 新型有效的他喷他多剂型
US20100143486A1 (en) 2008-12-10 2010-06-10 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
EP2381937A2 (en) 2008-12-31 2011-11-02 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
US20120149900A1 (en) 2009-01-09 2012-06-14 Tobias Ritter Fluorine containing compounds and methods of use thereof
US20100183687A1 (en) 2009-01-22 2010-07-22 Cox D Phillip Process for preparing particles of opioids and compositions produced thereby
CA2751627A1 (en) 2009-02-06 2010-08-12 Egalet Ltd. Pharmaceutical compositions resistant to abuse
ES2440595T3 (es) 2009-02-17 2014-01-29 Mallinckrodt Llc Proceso para la alquilación reductora de normorfinanos
WO2010096788A1 (en) 2009-02-23 2010-08-26 Mallinckrodt Inc. (+)-morphinanium quaternary salts and processes for their production
US8563727B2 (en) 2009-02-23 2013-10-22 Mallinckrodt Llc (+)-morphinanium N-oxides and processes for their production
US20100227876A1 (en) 2009-03-06 2010-09-09 Rechfensen Llp Methods of Reducing Side Effects of Analgesics
MX347106B (es) 2009-03-10 2017-04-12 Euro-Celtique S A * Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
BRPI0924427A2 (pt) 2009-03-18 2016-01-26 Evonik Roehm Gmbh composição farmacêutica de liberação controlada, seu processo de preparação e uso da mesma
CN102355893A (zh) 2009-03-18 2012-02-15 赢创罗姆有限公司 采用含有中性乙烯基聚合物和赋形剂的包衣的具有耐乙醇影响的控释药物组合物
KR20110134510A (ko) 2009-04-02 2011-12-14 샤이어 엘엘씨 오피오이드의 신규한 디카르복실산 연결 아미노산 및 펩티드 프로드러그와 그 용도
EP2419398A4 (en) 2009-04-14 2012-11-28 Infiniton Ab PRO-BET WITH BETA-KETO-CARBOXYLIC ACID, BETA-KETO-CARBOXYLIC ACID SALT OR BETA-KETO-CARBOXYLIC ACID ESTERS FOR ACTIVE INHIBITION
US20100291151A1 (en) 2009-04-21 2010-11-18 Auspex Pharmaceuticals, Inc. 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
KR20170081748A (ko) 2009-04-24 2017-07-12 옴야 인터내셔널 아게 활성 성분의 방출 조절을 위한 미립자 물질
WO2010141505A1 (en) 2009-06-01 2010-12-09 Protect Pharmaceutical Corporation Abuse-resistant delivery systems
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
CN102803267A (zh) 2009-06-11 2012-11-28 马林克罗特有限公司 通过催化氢转移的6-α-氨基N-取代的吗啡喃的制备
FR2946533A1 (fr) 2009-06-12 2010-12-17 Ethypharm Sa Reduction des fluctuations plasmatiques d'opioides.
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
NZ596666A (en) 2009-07-22 2013-09-27 Gruenenthal Chemie Tamper-resistant dosage form for oxidation-sensitive opioids
GB0914338D0 (en) 2009-08-17 2009-09-30 Johnson Matthey Plc Improved process
US9493477B2 (en) 2009-09-08 2016-11-15 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
US20110077222A1 (en) 2009-09-30 2011-03-31 Mallinckrodt Inc. Sustained-Release Opiate and Opiate Derivative Compositions
ES2569925T3 (es) 2009-09-30 2016-05-13 Acura Pharmaceuticals, Inc. Métodos y composiciones de disuasión del abuso
CN103002881B (zh) 2010-05-10 2015-09-02 欧洲凯尔特公司 载有活性剂的颗粒与额外活性剂的组合
CN103002882B (zh) 2010-05-10 2016-03-02 欧洲凯尔特公司 不含活性剂之颗粒及包含其之片剂的制备
WO2011141488A2 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
GB201020895D0 (en) 2010-12-09 2011-01-26 Euro Celtique Sa Dosage form

Also Published As

Publication number Publication date
AP2012006606A0 (en) 2012-12-31
IL222772A0 (en) 2012-12-31
KR20130030260A (ko) 2013-03-26
TN2012000488A1 (en) 2014-04-01
DE112011101605T5 (de) 2013-04-25
CL2012003012A1 (es) 2014-02-21
BR112012028773A2 (pt) 2016-07-19
SG184523A1 (en) 2012-11-29
NZ603497A (en) 2015-02-27
AP3441A (en) 2015-10-31
NO20121414A1 (no) 2013-02-11
WO2011141488A2 (en) 2011-11-17
TW201503913A (zh) 2015-02-01
TWI590835B (zh) 2017-07-11
NI201200157A (es) 2013-02-05
AR083150A1 (es) 2013-02-06
ES2408343B2 (es) 2014-07-17
DK201270677A (en) 2012-11-05
KR101858797B1 (ko) 2018-05-16
CO6640216A2 (es) 2013-03-22
DK178741B1 (da) 2016-12-19
JP2013526508A (ja) 2013-06-24
IL222772B (en) 2018-11-29
GB2492037A (en) 2012-12-19
KR20150028367A (ko) 2015-03-13
TWI483748B (zh) 2015-05-11
ES2408343A2 (es) 2013-06-20
AU2011252039B2 (en) 2014-06-12
ZA201207603B (en) 2014-12-23
MX2012013119A (es) 2013-02-11
NZ700732A (en) 2015-08-28
CN102946870A (zh) 2013-02-27
ES2408343R1 (es) 2013-08-28
TW201206501A (en) 2012-02-16
MY157673A (en) 2016-07-15
ECSP12012236A (es) 2013-02-28
CR20120549A (es) 2013-03-08
SE1251371A1 (sv) 2012-12-27
GB201219275D0 (en) 2012-12-12
CN105832687A (zh) 2016-08-10
PE20130657A1 (es) 2013-06-15
CH705273B1 (de) 2016-06-15
GT201200304A (es) 2014-06-09
EP2568967B2 (en) 2022-07-27
US20130178492A1 (en) 2013-07-11
JP5671609B2 (ja) 2015-02-18
EP2568967A2 (en) 2013-03-20
AU2011252039A1 (en) 2012-11-08
CA2739751C (en) 2014-08-12
MX347105B (es) 2017-04-12
US9700508B2 (en) 2017-07-11
UA106278C2 (ru) 2014-08-11
WO2011141488A3 (en) 2012-04-05
EP2568967B1 (en) 2018-10-24
CA2739751A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201300146A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ МОДУЛЯТОРА c-МЕТ
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201391087A1 (ru) Оральные лекарственные формы препарата тазоцитиниба с модифицированным высвобождением
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201490037A1 (ru) Антагонисты trpv4
MX340188B (es) Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
PH12015500823A1 (en) Modified release formulations for oprozomib
EA201690974A1 (ru) Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
EA201400444A1 (ru) Производные 2-оксопиперидинила